EG18751A - Antibody - enzime conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells - Google Patents

Antibody - enzime conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells

Info

Publication number
EG18751A
EG18751A EG41988A EG41988A EG18751A EG 18751 A EG18751 A EG 18751A EG 41988 A EG41988 A EG 41988A EG 41988 A EG41988 A EG 41988A EG 18751 A EG18751 A EG 18751A
Authority
EG
Egypt
Prior art keywords
tumor cells
antibody
prodrugs
delivery
enzime
Prior art date
Application number
EG41988A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/211,301 external-priority patent/US4975278A/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of EG18751A publication Critical patent/EG18751A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
EG41988A 1987-08-04 1988-08-03 Antibody - enzime conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells EG18751A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8138287A 1987-08-04 1987-08-04
US16106888A 1988-02-26 1988-02-26
US07/211,301 US4975278A (en) 1988-02-26 1988-06-29 Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells

Publications (1)

Publication Number Publication Date
EG18751A true EG18751A (en) 1993-12-30

Family

ID=27373967

Family Applications (1)

Application Number Title Priority Date Filing Date
EG41988A EG18751A (en) 1987-08-04 1988-08-03 Antibody - enzime conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells

Country Status (19)

Country Link
EP (2) EP0540859B1 (fr)
JP (2) JP2738414B2 (fr)
KR (1) KR930006757B1 (fr)
AT (2) ATE162196T1 (fr)
AU (1) AU614532B2 (fr)
CA (1) CA1336887C (fr)
DE (2) DE3853028T2 (fr)
DK (1) DK175406B1 (fr)
EG (1) EG18751A (fr)
ES (1) ES2068191T3 (fr)
FI (1) FI98197C (fr)
GR (1) GR3015065T3 (fr)
HU (1) HU207230B (fr)
IE (2) IE68309B1 (fr)
IL (1) IL87319A (fr)
NO (1) NO178138C (fr)
NZ (1) NZ225599A (fr)
PT (2) PT88187B (fr)
YU (1) YU150888A (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
DE69019959T2 (de) * 1989-01-23 1995-10-05 Akzo Nobel Nv Ortspezifische in-vivo-aktivierung von therapeutischen arzneimitteln.
AU633867B2 (en) * 1989-02-02 1993-02-11 Eli Lilly And Company Delivery of cytotoxic agents
GB8907617D0 (en) * 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8919607D0 (en) * 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
DE3935016A1 (de) * 1989-10-20 1991-04-25 Behringwerke Ag Glycosyl-etoposid-prodrugs, verfahren zu ihrer herstellung und ihre anwendung in kombination mit funktionalisiertem tumorspezifischen enzym-konjugaten
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
US6610299B1 (en) 1989-10-19 2003-08-26 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US6475486B1 (en) 1990-10-18 2002-11-05 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
FI94362C (fi) * 1989-10-20 1995-08-25 Squibb Bristol Myers Co Oleellisesti puhdistettu sulfataasi, menetelmä sen valmistamiseksi ja sitä tuottava Streptomyces-kanta
US5270196A (en) * 1989-10-20 1993-12-14 Bristol-Myers Squibb Company Arylsulfatase from streptomyces
US7241595B2 (en) 1989-10-20 2007-07-10 Sanofi-Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
JP3032287B2 (ja) * 1989-12-11 2000-04-10 イムノメデイツクス・インコーポレイテツド 診断薬または治療薬の抗体ターゲティング
EP0505566A1 (fr) * 1989-12-15 1992-09-30 Takeda Chemical Industries, Ltd. Anticorps biospecifique des cellules cancereuses et enzyme presentant des caracteristiques d'activation promedicamenteuse
GB9001641D0 (en) * 1990-01-24 1990-03-21 Imp Cancer Res Tech Compounds
KR920007937B1 (ko) * 1990-01-30 1992-09-19 현대자동차 주식회사 밸브시트용 철(Fe)계 소결합금
DE4002888A1 (de) * 1990-02-01 1991-08-08 Behringwerke Ag Anthracyclin-glycosyl-prodrugs, verfahren zu ihrer herstellung und ihre verwendung in kombination mit funktionalisierten tumorspezifischen enzymkonjugaten
CA2078118C (fr) * 1990-04-25 1999-11-16 Paul A. Aristoff Analogues de cc-1065
AU649275B2 (en) * 1990-11-06 1994-05-19 Bristol-Myers Squibb Company Prodrugs for beta-lactamase and uses thereof
GB9200417D0 (en) 1992-01-09 1992-02-26 Bagshawe Kenneth D Cytotoxic drug therapy
DE4233152A1 (de) 1992-10-02 1994-04-07 Behringwerke Ag Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung
EP0647450A1 (fr) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Prodrogues améliorées pour activation médiée par enzyme
US5459248A (en) * 1993-11-04 1995-10-17 Bristol-Myers Squibb Company Process of preparing etoposide phosphate and etoposide
DE4417865A1 (de) * 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie
US5516679A (en) * 1994-12-23 1996-05-14 Bristol-Myers Squibb Company Penicillin V amidohydrolase gene from Fusarium oxysporum
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
JPH1160499A (ja) * 1997-08-22 1999-03-02 Hiroshi Maeda 抗腫瘍剤
US6159706A (en) * 1997-12-23 2000-12-12 Newbiotics, Inc. Application of enzyme prodrugs as anti-infective agents
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
WO2000067796A1 (fr) 1999-05-07 2000-11-16 Genentech, Inc. Traitement de maladies auto-immunes au moyen d'antagonistes se liant aux marqueurs de surface de lymphocytes b
US7514067B2 (en) 2000-04-25 2009-04-07 President And Fellows Of Harvard College Methods for tumor diagnosis and therapy
WO2001093826A1 (fr) * 2000-06-06 2001-12-13 Sumitomo Pharmaceuticals Company, Limited Preparations polymere synthetiques biocompatibles
US7445802B2 (en) 2000-12-26 2008-11-04 Yeda Research And Development Co. Ltd Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases
WO2003048166A1 (fr) * 2001-12-03 2003-06-12 Universitätsklinikum Charite Der Humboldt-Universität Zu Berlin Technologie Transferstelle Podophyllotoxines en tant qu'agents antiproliferatifs
US6756397B2 (en) * 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
CA2562711C (fr) * 2004-04-15 2013-09-17 Genencor International, Inc. Molecules cab
EP2061493A4 (fr) * 2006-08-21 2011-01-12 Essential Skincare Llc Compositions pour réduire ou prévenir le cancer de la peau
MX2020006822A (es) * 2018-01-04 2020-09-03 Shanghai Lumosa Therapeutics Co Ltd Proteinas de fusion de anticuerpo de un solo dominio-citosina desaminasa.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1578734A (fr) * 1967-11-28 1969-08-22
FR2122695A5 (en) * 1971-01-20 1972-09-01 Rhone Poulenc Sa Antibiotics duborimycin and 27706rp - by reduction of daunorubicin and adriamycin
FR2397425A1 (fr) 1977-07-11 1979-02-09 Rhone Poulenc Ind Nouveaux derives de la daunorubicine, leur preparation et les compositions qui les contiennent
CA1168150A (fr) * 1981-12-18 1984-05-29 The Governors Of The University Of Alberta Conjugats d'albumine et d'agents therapeutiques
FR2523445A1 (fr) * 1982-03-17 1983-09-23 Sanofi Sa Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues
EP0142905A2 (fr) 1983-03-30 1985-05-29 Bio-Response Inc. Substance thérapeutique pour le traitement de maladies telles que le cancer
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
EP0202245A1 (fr) * 1984-11-23 1986-11-26 Sri International Analogues c-glycosidiques d'adriamycine
US4906562A (en) 1984-12-21 1990-03-06 Oncogen Monocolonal antibodies and antigen for human non-small cell lung carcinomas
DE3500023A1 (de) * 1985-01-02 1986-07-10 Farmitalia Carlo Erba S.p.A., Mailand/Milano 4'-desoxyanthracyclinester
FR2584294B1 (fr) * 1985-07-08 1992-02-21 Berdal Pascal Compositions pharmaceutiques a visee cytotrophique
GB8528761D0 (en) * 1985-11-22 1985-12-24 Axon Healthcare Ltd Enzyme-coupled antibodies
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems

Also Published As

Publication number Publication date
PT88187A (pt) 1989-06-30
FI98197B (fi) 1997-01-31
ES2068191T3 (es) 1995-04-16
KR930006757B1 (ko) 1993-07-23
NO883414D0 (no) 1988-08-02
DE3853028T2 (de) 1995-12-14
DE3856112T2 (de) 1998-08-27
ATE118354T1 (de) 1995-03-15
IE68309B1 (en) 1996-06-12
PT88187B (pt) 1995-12-29
EP0302473A2 (fr) 1989-02-08
EP0540859B1 (fr) 1998-01-14
DE3856112D1 (de) 1998-02-19
AU614532B2 (en) 1991-09-05
PT101702B (pt) 1999-11-30
PT101702A (pt) 1996-01-31
FI883597A (fi) 1989-02-05
GR3015065T3 (en) 1995-05-31
EP0302473A3 (en) 1990-01-17
NZ225599A (en) 1991-09-25
HU207230B (en) 1993-03-29
FI883597A0 (fi) 1988-08-01
JP3127136B2 (ja) 2001-01-22
CA1336887C (fr) 1995-09-05
JPH10130295A (ja) 1998-05-19
NO883414L (no) 1989-02-06
IE882379L (en) 1989-02-04
IL87319A (en) 1995-08-31
FI98197C (fi) 1997-05-12
DK175406B1 (da) 2004-09-27
YU150888A (en) 1990-06-30
IE950981L (en) 1989-02-04
DE3853028D1 (de) 1995-03-23
NO178138B (no) 1995-10-23
EP0302473B1 (fr) 1995-02-15
HUT47437A (en) 1989-03-28
IL87319A0 (en) 1990-02-09
DK434188A (da) 1989-02-05
EP0540859A1 (fr) 1993-05-12
DK434188D0 (da) 1988-08-03
NO178138C (no) 1996-01-31
AU2020188A (en) 1989-05-25
KR890003408A (ko) 1989-04-14
JP2738414B2 (ja) 1998-04-08
ATE162196T1 (de) 1998-01-15
JPH02223532A (ja) 1990-09-05

Similar Documents

Publication Publication Date Title
EG18751A (en) Antibody - enzime conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
IL88428A0 (en) Anti-tumor drug-monoclonal antibody conjugates
TW272971B (fr)
GR3017120T3 (en) Amine derivatives of anthracycline antibiotics.
AU633867B2 (en) Delivery of cytotoxic agents
EP0745390A3 (fr) Prodrogues polymériques pour bêta-lactamase et leurs utilisations
MY103598A (en) Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells.
ES2113904T3 (es) Profarmacos de antraciclinas.